What is the management of high-risk localized prostate cancer (CA prostate)?

Management of High-Risk Localized Prostate Cancer

Primary Treatment Recommendation

For high-risk localized prostate cancer, the standard of care is external beam radiation therapy (EBRT) combined with long-course androgen deprivation therapy (ADT) for 18-36 months, which has demonstrated superior overall survival and disease-specific mortality reduction compared to single-modality treatments. 1, 2

---

Treatment Options and Evidence-Based Approach

First-Line Treatment: Radiation Therapy + ADT

Radiation therapy combined with long-term ADT is the most strongly supported approach:

• ADT duration should be 18-36 months when combined with EBRT for high-risk disease 1, 2
• The EORTC 22863 trial demonstrated that 3 years of ADT plus 70 Gy radiation improved both prostate cancer-specific survival (HR 0.38,95% CI 0.24-0.60) and overall survival (HR 0.60,95% CI 0.45-0.80) compared to radiation alone 1
• A subsequent trial showed no difference between 18 versus 36 months of ADT, establishing 18 months as the minimum threshold 1, 3
• Radiation doses between 78-80+ Gy provide improved PSA-assessed disease control and should be delivered using intensity-modulated radiation therapy (IMRT) techniques 2
• Image-guided radiation therapy (IGRT) is required when doses ≥78 Gy are used to improve oncologic outcomes and reduce side effects 2

Radiation Therapy Enhancement Strategies

Consider pelvic lymph node irradiation for high-risk patients:

• Elective nodal irradiation may be offered given reasonable morbidity profile and reductions in biochemical failure and distant metastases, despite not showing overall survival benefit 1, 2
• Higher late grade II genitourinary toxicity occurs with whole pelvis radiation, but no difference in grade III/IV toxicity 1

Brachytherapy boost can be added to EBRT:

• Combination EBRT plus brachytherapy (low-dose-rate or high-dose-rate) improves coverage of the periprostatic space 2
• Analysis of 12,745 high-risk patients showed brachytherapy plus EBRT lowered disease-specific mortality compared to EBRT alone (HR 0.77,95% CI 0.66-0.90) 1, 2
• Trimodality treatment (EBRT + brachytherapy + ADT) achieved 9-year progression-free survival of 87% and disease-specific survival of 91% 1, 2

Alternative Treatment: Radical Prostatectomy

Radical prostatectomy is an acceptable alternative but requires careful patient selection:

• RP may lower the risk of cancer recurrence and improve survival compared to watchful waiting 1
• Non-nerve-sparing prostatectomy is typically required for high-risk disease 1
• Extended pelvic lymph node dissection should be performed when RP is chosen for high-risk disease 4, 5
• Recurrence rates remain high with surgery alone, and many patients will require adjuvant or salvage therapy 1

Multimodal approach with surgery:

• Patients with pathological stage ≥T3N0 and/or positive surgical margins should receive adjuvant RT + 24 months ADT 6
• This tailored approach achieved 5-year biochemical progression-free survival of 97% with surgery alone versus 91% with adjuvant RT+ADT 6

Active Surveillance

Active surveillance is technically an option but carries substantial risk:

• While listed as an option in guidelines, the high risk of disease progression and death makes active treatment strongly preferred 1
• This approach should only be considered in highly selected patients who understand the significant risks 1

---

Treatment Selection Algorithm

Step 1: Assess patient candidacy for definitive treatment

• If life expectancy <5-10 years or significant comorbidities: Consider palliative ADT alone 1, 4
• If symptomatic with limited life expectancy: Palliative ADT for symptom control 1

Step 2: For patients suitable for curative treatment, choose primary modality:

• Preferred: EBRT (78-80+ Gy with IMRT/IGRT) + ADT (18-36 months) 1, 2
• Consider adding: Pelvic nodal irradiation 1, 2
• Consider adding: Brachytherapy boost to EBRT 1, 2
• Alternative: Radical prostatectomy with extended pelvic lymph node dissection 4, 5

Step 3: If radical prostatectomy chosen, plan for adjuvant therapy:

• Adjuvant RT + ADT (24 months) for pathological stage ≥T3N0 or positive margins 6
• Salvage RT + ADT for biochemical recurrence 6

Step 4: Consider novel agents in appropriate settings:

• Abiraterone plus prednisone can be added to ADT for locally advanced disease based on STAMPEDE trial data 4

---

Critical Adverse Effects and Counseling Points

Patients must be informed of treatment-related morbidity:

• All treatments for high-risk disease (non-nerve-sparing prostatectomy, high-dose radiation, or radiation + ADT) are associated with high risk of erectile dysfunction 1
• ADT with radiation increases likelihood and severity of sexual dysfunction and causes systemic side effects including hot flashes, osteoporosis, metabolic syndrome, and cardiovascular effects 2, 4
• Urinary incontinence risk varies by modality, with higher rates after radical prostatectomy 1
• Bowel toxicity is primarily associated with radiation therapy 1

---

Common Pitfalls to Avoid

Do not use primary ADT alone as definitive treatment:

• ADT monotherapy is only appropriate for palliation in patients with limited life expectancy who cannot tolerate definitive local therapy 1, 2
• First-line hormone therapy is seldom indicated except for symptomatic patients whose life expectancy is too short to benefit from curative treatment 1

Do not use inadequate ADT duration:

• When combining ADT with radiation, minimum duration is 18 months; 24-36 months is standard 1, 2
• Shorter courses (4-6 months) are insufficient for high-risk disease 2

Do not use brachytherapy alone:

• Monotherapy with brachytherapy is not appropriate for high-risk disease 1
• If brachytherapy is used, it must be combined with EBRT and ADT 1, 2

Do not use conventional imaging alone for staging:

• PSMA PET imaging improves detection but should be used cautiously, as treatment recommendations are based on patients staged with conventional imaging 1
• Prospective validation is needed before substantially altering standard treatments based on PSMA PET results 1

Do not omit extended pelvic lymph node dissection if performing surgery:

• Extended PLND is essential for accurate staging when radical prostatectomy is chosen for high-risk disease 4, 5